These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37602144)

  • 21. Randomised controlled trial of high versus ad libitum water intake in patients with autosomal dominant polycystic kidney disease: rationale and design of the DRINK feasibility trial.
    El-Damanawi R; Lee M; Harris T; Mader LB; Bond S; Pavey H; Sandford RN; Wilkinson IB; Burrows A; Woznowski P; Ben-Shlomo Y; Karet Frankl FE; Hiemstra TF
    BMJ Open; 2018 May; 8(5):e022859. PubMed ID: 29743334
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The AMBER care bundle for hospital inpatients with uncertain recovery nearing the end of life: the ImproveCare feasibility cluster RCT.
    Koffman J; Yorganci E; Murtagh F; Yi D; Gao W; Barclay S; Pickles A; Higginson I; Johnson H; Wilson R; Bailey S; Ewart C; Evans C
    Health Technol Assess; 2019 Oct; 23(55):1-150. PubMed ID: 31594555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of framing and communicating COVID-19 vaccine side-effect risks on vaccine intentions for adults in the UK and the USA: A structured summary of a study protocol for a randomized controlled trial.
    Sudharsanan N; Favaretti C; Hachaturyan V; Bärnighausen T; Vandormael A
    Trials; 2021 Sep; 22(1):592. PubMed ID: 34488843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomised controlled trial to determine the efficacy and safety of prescribed water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD).
    Wong ATY; Mannix C; Grantham JJ; Allman-Farinelli M; Badve SV; Boudville N; Byth K; Chan J; Coulshed S; Edwards ME; Erickson BJ; Fernando M; Foster S; Haloob I; Harris DCH; Hawley CM; Hill J; Howard K; Howell M; Jiang SH; Johnson DW; Kline TL; Kumar K; Lee VW; Lonergan M; Mai J; McCloud P; Peduto A; Rangan A; Roger SD; Sud K; Torres V; Vilayur E; Rangan GK
    BMJ Open; 2018 Jan; 8(1):e018794. PubMed ID: 29358433
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interventions for preventing the progression of autosomal dominant polycystic kidney disease.
    Bolignano D; Palmer SC; Ruospo M; Zoccali C; Craig JC; Strippoli GF
    Cochrane Database Syst Rev; 2015 Jul; 2015(7):CD010294. PubMed ID: 26171904
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Cure SMA Clinical Trial Experience Survey: A Study of Trial Participant Perspectives on Clinical Trial Management and Patient-Centric Management Practices.
    Peterson IS; Mazzella AJ; Belter LT; Curry MA; Cruz RE; Jarecki J
    Neurol Ther; 2022 Sep; 11(3):1167-1181. PubMed ID: 35635603
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Behavioural activation therapy for post-stroke depression: the BEADS feasibility RCT.
    Thomas SA; Drummond AE; Lincoln NB; Palmer RL; das Nair R; Latimer NR; Hackney GL; Mandefield L; Walters SJ; Hatton RD; Cooper CL; Chater TF; England TJ; Callaghan P; Coates E; Sutherland KE; Eshtan SJ; Topcu G
    Health Technol Assess; 2019 Sep; 23(47):1-176. PubMed ID: 31524133
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Psychological interventions for people with hemophilia.
    Palareti L; Melotti G; Cassis F; Nevitt SJ; Iorio A
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD010215. PubMed ID: 32187661
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Randomized Clinical Trial of Metformin to Treat Autosomal Dominant Polycystic Kidney Disease.
    Seliger SL; Abebe KZ; Hallows KR; Miskulin DC; Perrone RD; Watnick T; Bae KT
    Am J Nephrol; 2018; 47(5):352-360. PubMed ID: 29779024
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Caregiver Burden of Autosomal Dominant Polycystic Kidney Disease: A Qualitative Study.
    Oberdhan D; Palsgrove AC; Cole JC; Harris T
    Kidney Med; 2023 Feb; 5(2):100587. PubMed ID: 36686593
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overview of the epidemiology methods and applications: strengths and limitations of observational study designs.
    Colditz GA
    Crit Rev Food Sci Nutr; 2010; 50 Suppl 1(s1):10-2. PubMed ID: 21132580
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
    Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT
    Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mineralocorticoid Antagonism and Vascular Function in Early Autosomal Dominant Polycystic Kidney Disease: A Randomized Controlled Trial.
    Nowak KL; Gitomer B; Farmer-Bailey H; Wang W; Malaczewski M; Klawitter J; You Z; George D; Patel N; Jovanovich A; Chonchol M
    Am J Kidney Dis; 2019 Aug; 74(2):213-223. PubMed ID: 30803706
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized clinical trial to compare the efficacy of ivermectin versus placebo to negativize nasopharyngeal PCR in patients with early COVID-19 in Peru (SAINT-Peru): a structured summary of a study protocol for randomized controlled trial.
    Garcia PJ; Mundaca H; Ugarte-Gil C; Leon P; Malaga G; Chaccour C; Carcamo CP
    Trials; 2021 Apr; 22(1):262. PubMed ID: 33836826
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic enrichment design in clinical trials for autosomal dominant polycystic kidney disease: the HALT-PKD clinical trial.
    Irazabal MV; Abebe KZ; Bae KT; Perrone RD; Chapman AB; Schrier RW; Yu AS; Braun WE; Steinman TI; Harris PC; Flessner MF; Torres VE;
    Nephrol Dial Transplant; 2017 Nov; 32(11):1857-1865. PubMed ID: 27484667
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic Area Data Standards for Autosomal Dominant Polycystic Kidney Disease: A Report From the Polycystic Kidney Disease Outcomes Consortium (PKDOC).
    Perrone RD; Neville J; Chapman AB; Gitomer BY; Miskulin DC; Torres VE; Czerwiec FS; Dennis E; Kisler B; Kopko S; Krasa HB; LeRoy E; Castedo J; Schrier RW; Broadbent S
    Am J Kidney Dis; 2015 Oct; 66(4):583-90. PubMed ID: 26088508
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of Renin-Angiotensin-Aldosterone System blockade in patients admitted to hospital with confirmed coronavirus disease (COVID-19) infection (The McGill RAAS-COVID- 19): A structured summary of a study protocol for a randomized controlled trial.
    Aflaki M; Flannery A; Ferreira JP; Cheng MP; Kronfli N; Marelli A; Zannad F; Brophy J; Afillalo J; Huynh T; Giannetti N; Bessissow A; Ezekowitz JA; Lopes RD; Ambrosy AP; Craig M; Sharma A
    Trials; 2021 Feb; 22(1):115. PubMed ID: 33546734
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.